Vistagen to present at the 2024 anxiety and depression association (adaa) conference

South san francisco, calif.--(business wire)---- $vtgn #mentalhealth--vistagen (nasdaq: vtgn), a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced that it will present posters detailing clinical trial data for fasedienol, an investigational pherine candidate in phase 3 development for the acute treatment of social anxiety disorder (sad), and ph80, a phase 2 investigational pherine.
VTGN Ratings Summary
VTGN Quant Ranking